2,697 Shares in AbbVie Inc. $ABBV Bought by Wealth Science Advisors LLC

Wealth Science Advisors LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, HoldingsChannel reports. The fund acquired 2,697 shares of the company’s stock, valued at approximately $616,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Diversified Trust Co raised its position in shares of AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after buying an additional 10,891 shares during the last quarter. Permanent Capital Management LP acquired a new stake in AbbVie during the third quarter worth about $720,000. Railway Pension Investments Ltd increased its position in AbbVie by 33.0% during the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares during the last quarter. World Investment Advisors increased its position in shares of AbbVie by 9.4% during the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after acquiring an additional 9,811 shares during the last quarter. Finally, Public Sector Pension Investment Board increased its position in shares of AbbVie by 17.0% during the third quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company’s stock valued at $241,888,000 after acquiring an additional 151,644 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre pharmaceutical manufacturing campus in Durham, NC — its largest-ever single-site capital investment — which management says will add advanced, AI-enabled production capacity for immunology, neuroscience and oncology drugs and create hundreds of jobs; investors view this as a long-term capacity and supply-chain strengthening move. Read More.
• Positive Sentiment: Analyst sentiment turned more constructive: Canaccord initiated coverage with a Strong Buy / $262 price target, which supports upside expectations and likely helped buying interest after the campus announcement. Read More.
• Neutral Sentiment: AbbVie struck an exclusive licensing deal with Haisco to develop pain medicines (AbbVie will own development/manufacturing/commercial rights) — a potentially positive medium-term pipeline expansion, but impact depends on development milestones and commercialization timing. Read More.
• Neutral Sentiment: Investors are also watching upcoming Q1 earnings (Apr. 29) and consensus estimates; previews and models are circulating (Zacks and others) and could re-rate the name depending on results vs. guidance. Read More.
• Negative Sentiment: The FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE (TrenibotE) BLA, citing manufacturing-process concerns; the agency did not request new clinical studies but requires AbbVie to resolve manufacturing questions before approval — this delays a potential new product launch and creates near-term revenue uncertainty for the neurotoxin program. Read More.
• Negative Sentiment: Regulatory focus on manufacturing (FDA requests for additional information / manufacturing concerns highlighted in multiple reports) increases scrutiny on AbbVie’s production controls and could raise near-term remediation costs or timelines. AbbVie says it is well-positioned to address the FDA’s comments, but the issue tempers enthusiasm until resolved. Read More.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $200.97 on Friday. The firm has a market capitalization of $355.34 billion, a P/E ratio of 85.15, a PEG ratio of 0.72 and a beta of 0.38. AbbVie Inc. has a one year low of $176.11 and a one year high of $244.81. The company’s fifty day moving average is $217.33 and its two-hundred day moving average is $222.62.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 14.22 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. AbbVie’s payout ratio is currently 293.22%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ABBV. William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Barclays initiated coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Finally, Evercore cut their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $253.19.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.